Human Longevity, Inc.
Edit

Human Longevity, Inc.

https://www.humanlongevity.com/
Last activity: 04.08.2026
Active
Categories: CareDataDatabaseHealthTechHumanLearnLifePersonalResearchTechnology
Human Longevity, Inc. ™ (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries from these data to generate personalized health insights. Our goal is to extend healthy human life by revolutionizing human health and transforming the practice of medicine. Our DNA determines so much about each of us, but other factors can also influence our health. HLI is focused on compiling and analyzing more genotypic and phenotypic data because the combination of both enables us —to generate unprecedented insights and accelerate our understanding into what makes us who we are and what we can change for a life better lived.
Followers
22.78K
Website visits
4.9K /mo.
Mentions
146
Location: United States, California, San Diego
Employees: 51-200
Total raised: $39.8M
Founded date: 2013

Investors 3

Funding Rounds 1

DateSeriesAmountInvestors
22.08.2024Series B$39.8M-

Mentions in press and media 146

DateTitleDescription
04.08.2026Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599The same genomic technology once limited to specialist programs is now accessible to anyone, paired with an AI platform built on over a decade of clinical data and a new multimillion-dollar collaboration with Insilico Medicine to predict di...
22.07.2026Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain ManagementAI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class, brain-penetrant, non-opioid solution for pain management. Superior Therapeutic Profile: ...
15.07.2026Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and DevelopmentCombines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 15, 2026 /PRNewswire/ -- ...
09.07.2026Insilico Medicine Releases Positive Profit Alert for the First Half of 2026CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive prof...
07.07.2026Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary FibrosisPotentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in N...
22.06.2026Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune DisordersCAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company lea...
19.06.2026Gero Raises $17 Million To Slow AgingGero announced it has raised $17 million in new financing, bringing its total equity funding to $34 million. The company is developing medicines designed to slow aging and treat age-related diseases by combining longitudinal human data, AI,...
17.06.2026Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia TherapeuticsCAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved t...
26.05.2026Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity ScienceCambridge, Mass., May 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Human Life Foundation Models, Inc. (HLFM), a newly ...
18.06.2025Why Claims Data Alone Leave Gaps in Understanding the Patient JourneyNoah Nasser, CEO at datma In today’s precision medicine landscape, pharmaceutical companies and access teams face a critical challenge: understanding not just whether therapies work, but how they are accessed, adopted, and experienced by re...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In